We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
Read MoreHide Full Article
Key Takeaways
Sanofi dropped KT-474 but advanced Kymera's IRAK4 degrader KT-485 into clinical development.
Gilead signed a $750M deal with Kymera to develop CDK2-targeting molecular glue degraders.
KT-621 showed strong phase I results in atopic dermatitis, with phase 2b trials set for 2025-26.
It has been a roller coaster ride for Kymera Therapeutics (KYMR - Free Report) stock this year. This clinical-stage biotechnology company is pioneering the field of targeted protein degradation (TPD) to develop drugs for various immunological diseases.
The company has formed partnerships with bigwigs like Sanofi (SNY - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) to advance its pipeline.
KYMR’s Deal With Sanofi
In June 2025, Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical studies.
The candidate was discovered by Kymera.
KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration following extensive preclinical work supporting its robust development potential. The candidate is expected to advance into early-stage testing next year.
Consequently, Sanofi has decided to discontinue the development of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two Phase IIb dose-ranging studies.
Sanofi will no longer develop KT-474 and has decided to exercise its participation election right for the IRAK4 target under the terms of the collaboration agreement. Per the agreement, Kymera received a $20 million milestone payment in the second quarter of 2025 (related to preclinical activities associated with KT-485).
Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the initiation of phase I clinical testing.
KYMR Collaborates With GILD
In June 2025, Kymera entered into an exclusive option and license agreement with GILD to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the companies, CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.
While traditional inhibitors of CDK2 prevent it from working, they often interfere with similar proteins, leading to undesired side effects. In contrast, MGDs have the potential to provide more precise, safe, and effective treatments for cancers that rely on CDK2 activity by selectively removing this protein from cells.
Under the terms of the agreement, Kymera will receive an upfront payment of $85 million and potential option exercise payments. The total payments will range up to $750 million.
Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. While Kymera will lead all research activities for the CDK2 program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration if it exercises its option to exclusively license the program.
KYMR’s Progress With Other Candidates
Kymera’s novel TPD approach is promising, and the pipeline progress is encouraging.
Earlier in the year, KYMR announced positive clinical results from the phase I study on the investigational candidate, KT-621, an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation.
Data surpassed the company’s expectations and showed comparable efficacy to blockbuster atopic dermatitis (AD) drug Dupixent (dupilumab). A phase I study BroADen Phase 1b trial, an open label study in patients with moderate to severe AD, is ongoing, with data expected to be reported in the fourth quarter of 2025.
Two parallel phase IIb studies in AD and asthma patients are planned to be initiated in the fourth quarter of 2025 and the first quarter of 2026, respectively.
Kymera has selected a follow-on oral STAT6 degrader to KT-621, with a strong potency, selectivity, and safety profile, and has advanced it through all required IND-enabling studies.
Meanwhile, IND-enabling studies on KT-579 are ongoing. Kymera plans to advance the program into phase I testing in early 2026.
Our Take on KYMR’s Progress
Although the oncology deal with GILD appears promising and the resulting influx of cash is encouraging, there is still a long way to go.
Sanofi's decision to advance preclinical IRAK4 degrader KT-485 rather than advancing KT-474 delayed milestone payments for Kymera that could have been achieved on the potential approval of KT-474, which had moved to phase IIb studies in late 2023.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
Key Takeaways
It has been a roller coaster ride for Kymera Therapeutics (KYMR - Free Report) stock this year. This clinical-stage biotechnology company is pioneering the field of targeted protein degradation (TPD) to develop drugs for various immunological diseases.
The company has formed partnerships with bigwigs like Sanofi (SNY - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) to advance its pipeline.
KYMR’s Deal With Sanofi
In June 2025, Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical studies.
The candidate was discovered by Kymera.
KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration following extensive preclinical work supporting its robust development potential. The candidate is expected to advance into early-stage testing next year.
Consequently, Sanofi has decided to discontinue the development of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two Phase IIb dose-ranging studies.
Sanofi will no longer develop KT-474 and has decided to exercise its participation election right for the IRAK4 target under the terms of the collaboration agreement. Per the agreement, Kymera received a $20 million milestone payment in the second quarter of 2025 (related to preclinical activities associated with KT-485).
Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the initiation of phase I clinical testing.
KYMR Collaborates With GILD
In June 2025, Kymera entered into an exclusive option and license agreement with GILD to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the companies, CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.
While traditional inhibitors of CDK2 prevent it from working, they often interfere with similar proteins, leading to undesired side effects. In contrast, MGDs have the potential to provide more precise, safe, and effective treatments for cancers that rely on CDK2 activity by selectively removing this protein from cells.
Under the terms of the agreement, Kymera will receive an upfront payment of $85 million and potential option exercise payments. The total payments will range up to $750 million.
Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. While Kymera will lead all research activities for the CDK2 program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration if it exercises its option to exclusively license the program.
KYMR’s Progress With Other Candidates
Kymera’s novel TPD approach is promising, and the pipeline progress is encouraging.
Earlier in the year, KYMR announced positive clinical results from the phase I study on the investigational candidate, KT-621, an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation.
Data surpassed the company’s expectations and showed comparable efficacy to blockbuster atopic dermatitis (AD) drug Dupixent (dupilumab). A phase I study BroADen Phase 1b trial, an open label study in patients with moderate to severe AD, is ongoing, with data expected to be reported in the fourth quarter of 2025.
Two parallel phase IIb studies in AD and asthma patients are planned to be initiated in the fourth quarter of 2025 and the first quarter of 2026, respectively.
Kymera has selected a follow-on oral STAT6 degrader to KT-621, with a strong potency, selectivity, and safety profile, and has advanced it through all required IND-enabling studies.
Meanwhile, IND-enabling studies on KT-579 are ongoing. Kymera plans to advance the program into phase I testing in early 2026.
Our Take on KYMR’s Progress
Although the oncology deal with GILD appears promising and the resulting influx of cash is encouraging, there is still a long way to go.
Sanofi's decision to advance preclinical IRAK4 degrader KT-485 rather than advancing KT-474 delayed milestone payments for Kymera that could have been achieved on the potential approval of KT-474, which had moved to phase IIb studies in late 2023.